| Dr Jeffrey Kirk Wood, DDS | |
|
20 W. 1700 S., Clearfield, UT 84016-0074 | |
| (801) 416-4393 | |
| Not Available |
| Full Name | Dr Jeffrey Kirk Wood |
|---|---|
| Gender | Male |
| Speciality | Dentist - Dental Public Health |
| Location | 20 W. 1700 S., Clearfield, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740381490 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223D0001X | Dentist - Dental Public Health | 141719-9922 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey Kirk Wood, DDS 1971 E. Sunset Dr., Layton, UT 84040 Ph: (801) 547-9979 | Dr Jeffrey Kirk Wood, DDS 20 W. 1700 S., Clearfield, UT 84016-0074 Ph: (801) 416-4393 |
News Archive
A decades old grudge between former president Jimmy Carter and the late senator Edward Kennedy was renewed again Thursday when Carter criticized Kennedy's stand on the former president's health care proposal. CBS "60 Minutes" quotes Carter as saying "that Kennedy delayed comprehensive coverage for Americans for decades.
Middle-aged people with depressive symptoms who carry a genetic variation called apolipoprotein (APOE) ε4 may be more at risk to develop tau protein accumulations in the brain's emotion- and memory-controlling regions, a new study by researchers from The University of Texas Health Science Center at San Antonio and collaborating institutions suggests.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.
Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1).
Kaiser Permanente's National Pharmacy Programs and Services was recognized at the J.D. Power and Associates Customer Service Roundtable in Las Vegas as a J.D. Power 2011 Customer Service Champion — one of only 40 companies to have earned the distinction this year.
› Verified 4 days ago
Dr. Clifford Owen Sorensen, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 120 S State St, Suite C, Clearfield, UT 84015 Phone: 801-773-2252 | |
Dr. Bryan Steele Larson, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 22 S State St, Clearfield, UT 84015 Phone: 801-393-5355 | |
Dr. Clark J A Christensen, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 1435 S 1350 E, Clearfield, UT 84015 Phone: 801-825-9818 Fax: 801-825-1877 | |
Dr. Scott R Carlton, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1435 S 1350 E, Clearfield, UT 84015 Phone: 801-774-6567 Fax: 801-774-7326 | |
Matthew Keeffer, DMD Dentist Medicare: Medicare Enrolled Practice Location: 1435 S 1350 E, Clearfield, UT 84015 Phone: 801-773-6170 Fax: 801-773-3371 | |
Dr. Mark Lee Newey, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 938 S 2000 E Ste 100, Clearfield, UT 84015 Phone: 801-825-1116 | |
Dr. Charalabos G Goupios, DDS Dentist Medicare: Medicare Enrolled Practice Location: 573 N 1000 W, Clearfield, UT 84015 Phone: 801-776-1000 Fax: 801-776-5277 |